Recent Updates
Recently added Catalysts
ALDX Negative Sentiment Score: 30/100

ALDEYRA DEADLINE FRIDAY MAY 29th: Bragar Eagel & Squire, P.C. Urgently Reminds Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th

Key Takeaway: A class action lawsuit has been initiated against Aldeyra Therapeutics, alleging that the company made false and misleading statements regarding its business and clinical trial results. The lawsuit pertains to securities bought between November 3, 2023, and March 16, 2026, with a deadline for investor participation set for May 29, 2026. Key allegations include the inconsistency of results from clinical trials for reproxalap, which have rendered any positive findings questionable. Investors are encouraged to discuss their options with the law firm representing the case.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Aldeyra Therapeutics due to allegations of misleading statements.
  • The lawsuit claims that clinical trial results for reproxalap were inconsistent, affecting the reliability of positive findings.
  • Investors are being urged to contact the law firm due to significant financial losses incurred.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aldeyra (ALDX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired Aldeyra securities between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Aldeyra securities between November 3, 2023 and March 16, 2026, both dates inclusive (the “Class Period”). Investors have until May 29, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
What are the Allegation Details?
The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Aldeyra’s business, operations, and prospects, including allegations that: (1) the results of the reproxalap clinical trials were inconsistent; and (2) the inconsistency of the results rendered any positive findings from these trials unreliable and not meaningful.
What are the Next Steps?
If you purchased or otherwise acquired Aldeyra shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who can participate in the Aldeyra lawsuit?

Individuals who purchased Aldeyra securities between November 3, 2023, and March 16, 2026.

What are the allegations against Aldeyra Therapeutics?

The lawsuit claims Aldeyra made false statements about its clinical trial results.

How can I contact Bragar Eagel & Squire for help?

Call (212) 355-4648 or email investigations@bespc.com for assistance.

What is the deadline to become a lead plaintiff?

Investors have until May 29, 2026, to apply to be lead plaintiff in the lawsuit.

Is there a cost to discuss my rights regarding Aldeyra?

There is no cost or obligation to discuss your rights with Bragar Eagel & Squire.

Last updated: May 26, 2026